Trilinolein inhibits epinephrine-induced human platelet aggregation.
At concentrations ranging from 10(-9) to 10(-6) M, trilinolein inhibited epinephrine-induced platelet aggregation. This inhibition was accompanied by reduced ATP release and thromboxane B2 formation. However, concentration-response curves for the interaction between trilinolein and epinephrine showed that trilinolein was unlikely a competitive antagonist of epinephrine. Platelet aggregation induced by collagen, thrombin, ADP or arachidonic acid was not inhibited. This study supported the theory that this type of triglyceride may have therapeutic potential but the definite mechanism for its effect remains to be answered.
Lai
L J
LJ
Institute of Traditional Medicine, National Yang-Ming University Medical College, Taipei, Taiwan, ROC.
Shen
Y C
YC
Hong
C Y
CY
D004837:Epinephrine / Q000037:antagonists & inhibitors*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013929:Thromboxane B2 / Q000096:biosynthesis; D014280:Triglycerides / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D014280:Triglycerides; D013929:Thromboxane B2; C009564:trilinolein; D004837:Epinephrine